Profile

Quest PharmaTech Inc. (Quest) is a publicly traded (TSX Venture), Canadian based biotechnology company developing a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy, or immunoadjuvants. Quest's technology platform includes a series of monoclonal antibodies that target several different cancer markers such as CA125, MUC1, PSA, CA19.9 and TAG72. The Company believes that combinatorial immunotherapy which necessarily takes advantage of immune modulating effects of selected cytotoxic agents normally used as part of standard chemotherapy regimens, as well as the use of specific immunoadjuvants, will lead to important commercial applications of this immunology platform in the treatment of cancer. Quest's technologies and products are protected by more than 90 issued patents from fifteen different families covering more than 70% of the global market. The most advanced of these product candidates is Oregovomab, an anti-CA125 antibody in combination with front-line chemotherapy for the treatment of advanced ovarian cancer that is currently undergoing a Phase IIb clinical trial in 12 centers in Italy and U.S.

Overview

Quest is positioned as a drug development company focused on novel therapies for the treatment of cancer.

• Late stage product for ovarian cancer with excellent safety profile

• Competitive clinical advantage versus currently available immunomodulated approaches with strong profit potential

• Diversified product pipeline

• Patented technology platform